Are we under- or mistreating patients at the time of presentation?
Treatment goals in Crohn's disease (CD) are evolving beyond the control of symptoms towards deep remission, which encompasses clinical remission and mucosal healing. The ultimate goals are to prevent bowel damage, reduce long-term disability, and maintain normal quality of life. Until recently, goals of CD management focused on induction and maintenance of a symptomatic response, and little attention was paid to the delay or even prevention of disease progression. A very different approach is taken with other chronic diseases, such as hypertension, diabetes, and rheumatoid arthritis. This more comprehensive approach is often referred to as 'treat-to-target' strategy. The treat-to-target strategy defines a new treatment objective that aims to achieve and sustain both clinical remission and control of inflammation. With our new understanding of the etiopathophysiology of inflammatory bowel disease, are we mistreating our patients? The most convincing concept at this time is that of a defective mucosal barrier due to inappropriate recognition of the luminal flora or a defective defense against those bacteria. These recent theories indicate that the paradigm of immune suppression may not be the optimal concept. Therefore, a variety of approaches to improve the barrier function or to modulate luminal components have to be considered. We still have much to learn about these concepts in order to achieve the treatment goals of avoiding structural damage and complications.